Video: Developing the drug LB-100 to inhibit PP2A

Researchers at the National Institute of Health as well as the Netherlands Cancer Institute and the Medical University of Taiwan have independently found is that the enzyme protein phosphatase 2A plays an important role in the response of the immune system against cancer what they found is that if you inhibit this enzyme PP2A the cells that attack the tumor, the T-cells, are stimulated. They increase in number, are more active and they can better recognize the tumor. LB-100 is the drug that LIXTE is developing to inhibit PP2A in Phase One trials it has shown a favorable safety profile and we are now testing LB-100 in lung cancer sarcoma and ovarian cancer.